Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 23 · below the Ichimoku cloud · RSI 27 (oversold) · MACD below its signal · 4% above its 52-week low
None of the 29 investors followed here reported a position in 2158.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 2158.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 1, 2026 | Feng (Xiaoying)Chief Financial Officer | — | 637K | — |
| Oct 26, 2025 | Feng (Xiaoying)Chief Financial Officer | — | 33.6K | — |
| Jul 16, 2025 | Xie (Li)Director (Executive) | — | 16K | — |
| Jul 16, 2025 | Xie (Li)Director (Executive) | — | 5.4K | — |
| Apr 23, 2025 | Feng (Xiaoying)Chief Financial Officer | — | 456.1K | — |
| Apr 23, 2025 | Feng (Xiaoying)Chief Financial Officer | — | 800 | — |
| Apr 23, 2025 | Xie (Li)Director (Executive) | — | 79.3K | — |
| Apr 23, 2025 | Xie (Li)Director (Executive) | — | 19.9K | — |
| Jan 26, 2025 | Yan (Jun)Former | — | 22.1K | — |
| Jan 23, 2025 | Yan (Jun)Chief Technology Officer | Sale at price 0.53 per share. | 190K | $100.74K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.9 | 3.1 | -17.8 | 24.6 | -14.4 | -11.5 | -1.5 | -15.4 | -11.0 | -12.8 | −43.1% | ||
| 2025 | 5.9 | 25.5 | -2.5 | -6.3 | -0.7 | 0.9 | 10.8 | -5.7 | 8.7 | -13.8 | -9.5 | 2.3 | +10.3% |
| 2024 | -32.2 | 22.7 | -4.8 | 5.0 | -5.0 | -4.5 | -6.3 | -7.5 | 13.6 | -4.5 | 52.4 | -12.6 | −5.5% |
| 2023 | 8.5 | 29.6 | -14.7 | -19.4 | -15.9 | 15.9 | -1.6 | -29.9 | 0.3 | 4.3 | 17.8 | 3.5 | −17.0% |
| 2022 | -32.5 | -21.5 | -12.1 | -15.1 | -8.5 | 23.2 | -12.4 | -13.4 | -32.1 | -17.4 | 30.2 | 17.8 | −71.0% |
| 2021 | -0.1 | -26.8 | 18.9 | -1.7 | -1.7 | -18.6 | 3.0 | -24.4 | -3.3 | -14.0 | -2.1 | −56.6% |
Buy / hold / sell counts
Yidu Tech Inc., an investment holding company, provides healthcare solutions built on big data and artificial intelligence (AI) technologies in the People's Republic of China, Brunei, Singapore, and internationally. The company operates through AI for Medical, AI for Life Sciences, and AI for Care segments. The AI for Medical segment offers data intelligence platforms and data analytics-driven solutions, such as medical intelligent agent development and collaborative application solutions, Yidu smart management operational data center solutions, and dataset solutions based on disease-specific research databases. The AI for Life Sciences segment provides AI-powered intelligent services and solutions, including iCRO, an evidence driven solution in drug full life cycle; iEvidence, a lifecycle service solution for RWE based strategies; and iConsulting, an evidence-based analytics and market insight solution, as well as operates YiduCore, an AI medical brain. The AI for Care segment offers AI-enabled health management solutions to multi-level healthcare solutions for urban residents; distributes insurance companies' products; offers health management platform application and solution services; and sells pharmaceutical products. The company also offers insurance brokerage and technology services; and medical and computer technology research and development services. It serves healthcare industry participants, including hospitals, research institutions, insurance companies, regulators and policy makers, and doctors and patients, as well as pharmaceutical, biotech, and medical device companies. The company was formerly known as Happy Life Tech Inc. and changed its name to Yidu Tech Inc. in July 2020. Yidu Tech Inc. was incorporated in 2014 and is headquartered in Beijing, China.
No recent headlines.